Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Treatment for myeloma usually involves a type of radiation therapy called external beam radiation therapy. This type uses a machine outside of the body to aim radiation at the cancerous cells.

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

The applications are supported by data from the ongoing phase 3 AQUILA study (NCT03301220) of Darzalex Faspro as monotherapy for the treatment of adult patients with high-risk smoldering multiple ...

Genscript Biotech (HK:1548) has released an update. Genscript Biotech’s associate, Legend Biotech, is making strides in the treatment of ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.